A Study to Determine the Clinical Significance of Molecular Detection of Breast Cancer in the Blood of Stage IV Breast Cancer Patients
NCT ID: NCT00355316
Last Updated: 2013-06-21
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
224 participants
Study Classification
INTERVENTIONAL
Study Start Date
2005-11-30
Study Completion Date
2013-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study is designed to determine whether molecular detection of breast cancer cells in the peripheral blood of Stage IV breast cancer patients is a clinically relevant predictor of progression-free and overall survival. Stage IV breast cancer patients who have measurable breast cancer metastases and are initiating a regimen of systemic therapy are eligible for enrollment. Multi-marker real-time RT-PCR analysis will be performed on peripheral blood specimens from 92 breast cancer patients and 120 healthy volunteers. Peripheral blood specimens from breast cancer patients will be obtained at the time of study entry (prior to initiation of systemic therapy) and at serial time points during follow-up. Subjects will be followed longitudinally until death, although the study has been powered so that the primary objective can be addressed after 12 months of follow-up. Healthy volunteers will be asked to provide a blood sample at time of enrollment but will not be followed.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Blood Levels of Tumor Cells in Predicting Response in Patients Receiving First-Line Chemotherapy for Stage IV Breast Cancer
NCT00898014
Breast Cancer
COMPLETED
Study of Blood Samples in Patients With Breast Cancer
NCT00959556
Breast Cancer
UNKNOWN
Studying Blood Samples in Women With Breast Cancer or a History of Breast Cancer
NCT00898703
Breast Cancer
COMPLETED
Nutrition-Related Biomarkers in Predicting Breast Cancer Risk in Women
NCT00900367
Breast Cancer
ACTIVE_NOT_RECRUITING
Evaluation of Prognostic Monitoring for Women Who Have Completed Standard Treatment for Breast Cancer
NCT04145960
Breast Cancer
UNKNOWN
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Breast Neoplasms
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
BASIC_SCIENCE
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Stage IV Breast Cancer
Blood draws at baseline before systemic therapy. Blood draw then every 6 weeks for approximately 12 weeks.
Group Type
EXPERIMENTAL
Blood draw
Intervention Type
OTHER
Healthy Volunteers
Baseline blood draw.
Group Type
OTHER
Blood draw
Intervention Type
OTHER
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood draw
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Patient age must be \> 21 years.
2. Patient must have a tissue diagnosis of invasive breast cancer.
3. Patient must have documented evidence of metastatic disease.
4. Patient must have measurable lesions.
5. Patients must be initiating systemic therapy. Patients receiving hormonal therapy, and/or chemotherapy alone or in combination with other therapies are eligible.
6. Patient must have an ECOG performance status of 0, 1, or 2.
7. Patient must be available for follow-up.
8. Patient or their authorized legally acceptable representative must consent to be in the study and must have signed and dated an approved consent form which conforms to federal and institutional guidelines.
9. The patient with a previous history of non-breast malignancy is eligible for this study only if the patient meets the following criteria for a cancer survivor. A cancer survivor is eligible provided the following criteria are met: (1) patient has undergone potentially curative therapy for all prior malignancies, (2) patients have been considered disease free for at least 5 years (with the exception of basal cell or squamous cell carcinoma of the skin or carcinoma-in-situ of the cervix).
A volunteer will be eligible for inclusion in this study only if ALL of the following criteria apply:
1. Volunteer age must be \> 21 years.
2. Volunteer or their authorized legally acceptable representative must consent to be in the study and must have signed and dated an approved consent form which conforms to federal and institutional guidelines.
3. Patients with benign breast disease are eligible for enrollment.
4. The volunteer with a previous history of non-breast malignancy is eligible for this study only if the patient meets the following criteria for a cancer survivor. A cancer survivor is eligible provided both of the following criteria are met: (1) patient has undergone potentially curative therapy for all prior malignancies, (2) patient has been considered disease free for at least 5 years (with the exception of basal cell or squamous cell carcinoma of the skin or carcinoma-in-situ of the cervix).
2. Patient must have a tissue diagnosis of invasive breast cancer.
3. Patient must have documented evidence of metastatic disease.
4. Patient must have measurable lesions.
5. Patients must be initiating systemic therapy. Patients receiving hormonal therapy, and/or chemotherapy alone or in combination with other therapies are eligible.
6. Patient must have an ECOG performance status of 0, 1, or 2.
7. Patient must be available for follow-up.
8. Patient or their authorized legally acceptable representative must consent to be in the study and must have signed and dated an approved consent form which conforms to federal and institutional guidelines.
9. The patient with a previous history of non-breast malignancy is eligible for this study only if the patient meets the following criteria for a cancer survivor. A cancer survivor is eligible provided the following criteria are met: (1) patient has undergone potentially curative therapy for all prior malignancies, (2) patients have been considered disease free for at least 5 years (with the exception of basal cell or squamous cell carcinoma of the skin or carcinoma-in-situ of the cervix).
A volunteer will be eligible for inclusion in this study only if ALL of the following criteria apply:
1. Volunteer age must be \> 21 years.
2. Volunteer or their authorized legally acceptable representative must consent to be in the study and must have signed and dated an approved consent form which conforms to federal and institutional guidelines.
3. Patients with benign breast disease are eligible for enrollment.
4. The volunteer with a previous history of non-breast malignancy is eligible for this study only if the patient meets the following criteria for a cancer survivor. A cancer survivor is eligible provided both of the following criteria are met: (1) patient has undergone potentially curative therapy for all prior malignancies, (2) patient has been considered disease free for at least 5 years (with the exception of basal cell or squamous cell carcinoma of the skin or carcinoma-in-situ of the cervix).
Exclusion Criteria
A patient will be ineligible for inclusion in this study if ANY of the following criteria apply:
1. No documented metastatic disease.
2. No measurable lesions.
3. Bone only and/or brain metastasis.
4. Patient is not initiating a new regimen of systemic therapy.
1. No documented metastatic disease.
2. No measurable lesions.
3. Bone only and/or brain metastasis.
4. Patient is not initiating a new regimen of systemic therapy.
Minimum Eligible Age
18 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institutes of Health (NIH)
NIH
Sponsor Role
collaborator
Washington University School of Medicine
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
William E. Gillanders, M.D.
Role: PRINCIPAL_INVESTIGATOR
Washington University School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Washington University School of Medicine
St Louis, Missouri, United States
Site Status
Medical University of South Carolina
Charleston, South Carolina, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Valagussa P, Bonadonna G, Veronesi U. Patterns of relapse and survival following radical mastectomy. Analysis of 716 consecutive patients. Cancer. 1978 Mar;41(3):1170-8. doi: 10.1002/1097-0142(197803)41:33.0.co;2-i.
Reference Type
BACKGROUND
Ghossein RA, Carusone L, Bhattacharya S. Review: polymerase chain reaction detection of micrometastases and circulating tumor cells: application to melanoma, prostate, and thyroid carcinomas. Diagn Mol Pathol. 1999 Dec;8(4):165-75. doi: 10.1097/00019606-199912000-00001.
Reference Type
BACKGROUND
Diel IJ, Kaufmann M, Goerner R, Costa SD, Kaul S, Bastert G. Detection of tumor cells in bone marrow of patients with primary breast cancer: a prognostic factor for distant metastasis. J Clin Oncol. 1992 Oct;10(10):1534-9. doi: 10.1200/JCO.1992.10.10.1534.
Reference Type
BACKGROUND
Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW, Terstappen LW. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004 Oct 15;10(20):6897-904. doi: 10.1158/1078-0432.CCR-04-0378.
Reference Type
BACKGROUND
Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004 Aug 19;351(8):781-91. doi: 10.1056/NEJMoa040766.
Reference Type
BACKGROUND
Baker MK, Mikhitarian K, Osta W, Callahan K, Hoda R, Brescia F, Kneuper-Hall R, Mitas M, Cole DJ, Gillanders WE. Molecular detection of breast cancer cells in the peripheral blood of advanced-stage breast cancer patients using multimarker real-time reverse transcription-polymerase chain reaction and a novel porous barrier density gradient centrifugation technology. Clin Cancer Res. 2003 Oct 15;9(13):4865-71.
Reference Type
BACKGROUND
Berns EM, Klijn JG, van Putten WL, van Staveren IL, Portengen H, Foekens JA. c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. Cancer Res. 1992 Mar 1;52(5):1107-13.
Reference Type
BACKGROUND
Datta YH, Adams PT, Drobyski WR, Ethier SP, Terry VH, Roth MS. Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. J Clin Oncol. 1994 Mar;12(3):475-82. doi: 10.1200/JCO.1994.12.3.475.
Reference Type
BACKGROUND
Gasparini G, Toi M, Gion M, Verderio P, Dittadi R, Hanatani M, Matsubara I, Vinante O, Bonoldi E, Boracchi P, Gatti C, Suzuki H, Tominaga T. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst. 1997 Jan 15;89(2):139-47. doi: 10.1093/jnci/89.2.139.
Reference Type
BACKGROUND
Ioachim E, Kamina S, Athanassiadou S, Agnantis NJ. The prognostic significance of epidermal growth factor receptor (EGFR), C-erbB-2, Ki-67 and PCNA expression in breast cancer. Anticancer Res. 1996 Sep-Oct;16(5B):3141-7.
Reference Type
BACKGROUND
Anan K, Morisaki T, Katano M, Ikubo A, Tsukahara Y, Kojima M, Uchiyama A, Kuroki S, Torisu M, Tanaka M. Assessment of c-erbB2 and vascular endothelial growth factor mRNA expression in fine-needle aspirates from early breast carcinomas: pre-operative determination of malignant potential. Eur J Surg Oncol. 1998 Feb;24(1):28-33. doi: 10.1016/s0748-7983(98)80121-2.
Reference Type
BACKGROUND
Bieche I, Lazar V, Nogues C, Poynard T, Giovangrandi Y, Bellet D, Lidereau R, Vidaud M. Prognostic value of chorionic gonadotropin beta gene transcripts in human breast carcinoma. Clin Cancer Res. 1998 Mar;4(3):671-6.
Reference Type
BACKGROUND
Harbeck N, Dettmar P, Thomssen C, Henselmann B, Kuhn W, Ulm K, Janicke F, Hofler H, Graeff H, Schmitt M. Prognostic impact of tumor biological factors on survival in node-negative breast cancer. Anticancer Res. 1998 May-Jun;18(3C):2187-97.
Reference Type
BACKGROUND
Linderholm B, Tavelin B, Grankvist K, Henriksson R. Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J Clin Oncol. 1998 Sep;16(9):3121-8. doi: 10.1200/JCO.1998.16.9.3121.
Reference Type
BACKGROUND
Lockett MA, Baron PL, O'Brien PH, Elliott BM, Robison JG, Maitre N, Metcalf JS, Cole DJ. Detection of occult breast cancer micrometastases in axillary lymph nodes using a multimarker reverse transcriptase-polymerase chain reaction panel. J Am Coll Surg. 1998 Jul;187(1):9-16. doi: 10.1016/s1072-7515(98)00130-6.
Reference Type
BACKGROUND
Lockett MA, Metcalf JS, Baron PL, O'Brien PH, Elliott BM, Robison JG, Cole DJ. Efficacy of reverse transcriptase-polymerase chain reaction screening for micrometastic disease in axillary lymph nodes of breast cancer patients. Am Surg. 1998 Jun;64(6):539-43; discussion 543-4.
Reference Type
BACKGROUND
Molina R, Jo J, Filella X, Zanon G, Pahisa J, Mu noz M, Farrus B, Latre ML, Escriche C, Estape J, Ballesta AM. c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value. Breast Cancer Res Treat. 1998 Sep;51(2):109-19. doi: 10.1023/a:1005734429304.
Reference Type
BACKGROUND
Pathak KA, Khanna R, Khanna HD, Khanna S, Gupta S, Khanna NN. Carcinoembryonic antigen: an invaluable marker for advanced breast cancer. J Postgrad Med. 1996 Jul-Sep;42(3):68-71.
Reference Type
BACKGROUND
Mitas M, Mikhitarian K, Walters C, Baron PL, Elliott BM, Brothers TE, Robison JG, Metcalf JS, Palesch YY, Zhang Z, Gillanders WE, Cole DJ. Quantitative real-time RT-PCR detection of breast cancer micrometastasis using a multigene marker panel. Int J Cancer. 2001 Jul 15;93(2):162-71. doi: 10.1002/ijc.1312.
Reference Type
BACKGROUND
Gillanders WE, Mikhitarian K, Hebert R, Mauldin PD, Palesch Y, Walters C, Urist MM, Mann GB, Doherty G, Herrmann VM, Hill AD, Eremin O, El-Sheemy M, Orr RK, Valle AA, Henderson MA, Dewitty RL, Sugg SL, Frykberg E, Yeh K, Bell RM, Metcalf JS, Elliott BM, Brothers T, Robison J, Mitas M, Cole DJ. Molecular detection of micrometastatic breast cancer in histopathology-negative axillary lymph nodes correlates with traditional predictors of prognosis: an interim analysis of a prospective multi-institutional cohort study. Ann Surg. 2004 Jun;239(6):828-37; discussion 837-40. doi: 10.1097/01.sla.0000128687.59439.d6.
Reference Type
BACKGROUND
Mitas M, Hoover L, Silvestri G, Reed C, Green M, Turrisi AT, Sherman C, Mikhitarian K, Cole DJ, Block MI, Gillanders WE. Lunx is a superior molecular marker for detection of non-small cell lung cancer in peripheral blood [corrected]. J Mol Diagn. 2003 Nov;5(4):237-42. doi: 10.1016/s1525-1578(10)60480-1.
Reference Type
BACKGROUND
Campana D, Pui CH. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood. 1995 Mar 15;85(6):1416-34. No abstract available.
Reference Type
BACKGROUND
Cave H, Guidal C, Rohrlich P, Delfau MH, Broyart A, Lescoeur B, Rahimy C, Fenneteau O, Monplaisir N, d'Auriol L, et al. Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of delta and gamma T-cell receptor genes. Blood. 1994 Apr 1;83(7):1892-902.
Reference Type
BACKGROUND
Roberts WM, Estrov Z, Ouspenskaia MV, Johnston DA, McClain KL, Zipf TF. Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. N Engl J Med. 1997 Jan 30;336(5):317-23. doi: 10.1056/NEJM199701303360501.
Reference Type
BACKGROUND
Pallisgaard N, Clausen N, Schroder H, Hokland P. Rapid and sensitive minimal residual disease detection in acute leukemia by quantitative real-time RT-PCR exemplified by t(12;21) TEL-AML1 fusion transcript. Genes Chromosomes Cancer. 1999 Dec;26(4):355-65. doi: 10.1002/(sici)1098-2264(199912)26:43.0.co;2-3.
Reference Type
BACKGROUND
Mensink E, van de Locht A, Schattenberg A, Linders E, Schaap N, Geurts van Kessel A, De Witte T. Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR. Br J Haematol. 1998 Aug;102(3):768-74. doi: 10.1046/j.1365-2141.1998.00823.x.
Reference Type
BACKGROUND
Nakao M, Janssen JW, Flohr T, Bartram CR. Rapid and reliable quantification of minimal residual disease in acute lymphoblastic leukemia using rearranged immunoglobulin and T-cell receptor loci by LightCycler technology. Cancer Res. 2000 Jun 15;60(12):3281-9.
Reference Type
BACKGROUND
Emig M, Saussele S, Wittor H, Weisser A, Reiter A, Willer A, Berger U, Hehlmann R, Cross NC, Hochhaus A. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia. 1999 Nov;13(11):1825-32. doi: 10.1038/sj.leu.2401566.
Reference Type
BACKGROUND
Cassinat B, Zassadowski F, Balitrand N, Barbey C, Rain JD, Fenaux P, Degos L, Vidaud M, Chomienne C. Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR. Leukemia. 2000 Feb;14(2):324-8. doi: 10.1038/sj.leu.2401652.
Reference Type
BACKGROUND
Stathopoulou A, Vlachonikolis I, Mavroudis D, Perraki M, Kouroussis Ch, Apostolaki S, Malamos N, Kakolyris S, Kotsakis A, Xenidis N, Reppa D, Georgoulias V. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J Clin Oncol. 2002 Aug 15;20(16):3404-12. doi: 10.1200/JCO.2002.08.135.
Reference Type
BACKGROUND
Gradilone A, Gazzaniga P, Silvestri I, Gandini O, Trasatti L, Lauro S, Frati L, Agliano AM. Detection of CK19, CK20 and EGFR mRNAs in peripheral blood of carcinoma patients: correlation with clinical stage of disease. Oncol Rep. 2003 Jan-Feb;10(1):217-22.
Reference Type
BACKGROUND
Galan M, Vinolas N, Colomer D, Soler G, Munoz M, Longaron R, Ventura PJ, Gascon P, Estape J. Detection of occult breast cancer cells by amplification of CK19 mRNA by reverse transcriptase-polymerase chain reaction: role of surgical manipulation. Anticancer Res. 2002 Sep-Oct;22(5):2877-84.
Reference Type
BACKGROUND
Xenidis N, Vlachonikolis I, Mavroudis D, Perraki M, Stathopoulou A, Malamos N, Kouroussis C, Kakolyris S, Apostolaki S, Vardakis N, Lianidou E, Georgoulias V. Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer. Ann Oncol. 2003 Jun;14(6):849-55. doi: 10.1093/annonc/mdg259.
Reference Type
BACKGROUND
Weigelt B, Bosma AJ, Hart AA, Rodenhuis S, van 't Veer LJ. Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients. Br J Cancer. 2003 Apr 7;88(7):1091-4. doi: 10.1038/sj.bjc.6600868.
Reference Type
BACKGROUND
Zach O, Kasparu H, Krieger O, Hehenwarter W, Girschikofsky M, Lutz D. Detection of circulating mammary carcinoma cells in the peripheral blood of breast cancer patients via a nested reverse transcriptase polymerase chain reaction assay for mammaglobin mRNA. J Clin Oncol. 1999 Jul;17(7):2015-9. doi: 10.1200/JCO.1999.17.7.2015.
Reference Type
BACKGROUND
Bossolasco P, Ricci C, Farina G, Soligo D, Pedretti D, Scanni A, Deliliers GL. Detection of micrometastatic cells in breast cancer by RT-pCR for the mammaglobin gene. Cancer Detect Prev. 2002;26(1):60-3. doi: 10.1016/s0361-090x(02)00009-0.
Reference Type
BACKGROUND
Lin YC, Wu Chou YH, Liao IC, Cheng AJ. The expression of mammaglobin mRNA in peripheral blood of metastatic breast cancer patients as an adjunct to serum tumor markers. Cancer Lett. 2003 Feb 28;191(1):93-9. doi: 10.1016/s0304-3835(02)00545-1.
Reference Type
BACKGROUND
Zippelius A, Kufer P, Honold G, Kollermann MW, Oberneder R, Schlimok G, Riethmuller G, Pantel K. Limitations of reverse-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow. J Clin Oncol. 1997 Jul;15(7):2701-8. doi: 10.1200/JCO.1997.15.7.2701.
Reference Type
BACKGROUND
von Knebel Doeberitz M, Lacroix J. Nucleic acid based techniques for the detection of rare cancer cells in clinical samples. Cancer Metastasis Rev. 1999;18(1):43-64. doi: 10.1023/a:1006208303075.
Reference Type
BACKGROUND
Pantel K, Cote RJ, Fodstad O. Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst. 1999 Jul 7;91(13):1113-24. doi: 10.1093/jnci/91.13.1113.
Reference Type
BACKGROUND
Salerno CT, Frizelle S, Niehans GA, Ho SB, Jakkula M, Kratzke RA, Maddaus MA. Detection of occult micrometastases in non-small cell lung carcinoma by reverse transcriptase-polymerase chain reaction. Chest. 1998 Jun;113(6):1526-32. doi: 10.1378/chest.113.6.1526.
Reference Type
BACKGROUND
Castaldo G, Tomaiuolo R, Sanduzzi A, Bocchino ML, Ponticiello A, Barra E, Vitale D, Bariffi F, Sacchetti L, Salvatore F. Lung cancer metastatic cells detected in blood by reverse transcriptase-polymerase chain reaction and dot-blot analysis. J Clin Oncol. 1997 Nov;15(11):3388-93. doi: 10.1200/JCO.1997.15.11.3388.
Reference Type
BACKGROUND
Dingemans AM, Brakenhoff RH, Postmus PE, Giaccone G. Detection of cytokeratin-19 transcripts by reverse transcriptase-polymerase chain reaction in lung cancer cell lines and blood of lung cancer patients. Lab Invest. 1997 Sep;77(3):213-20.
Reference Type
BACKGROUND
Jung R, Kruger W, Hosch S, Holweg M, Kroger N, Gutensohn K, Wagener C, Neumaier M, Zander AR. Specificity of reverse transcriptase polymerase chain reaction assays designed for the detection of circulating cancer cells is influenced by cytokines in vivo and in vitro. Br J Cancer. 1998 Nov;78(9):1194-8. doi: 10.1038/bjc.1998.653.
Reference Type
BACKGROUND
Bostick PJ, Chatterjee S, Chi DD, Huynh KT, Giuliano AE, Cote R, Hoon DS. Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients. J Clin Oncol. 1998 Aug;16(8):2632-40. doi: 10.1200/JCO.1998.16.8.2632.
Reference Type
BACKGROUND
Martell M, Gomez J, Esteban JI, Sauleda S, Quer J, Cabot B, Esteban R, Guardia J. High-throughput real-time reverse transcription-PCR quantitation of hepatitis C virus RNA. J Clin Microbiol. 1999 Feb;37(2):327-32. doi: 10.1128/JCM.37.2.327-332.1999.
Reference Type
BACKGROUND
Bieche I, Olivi M, Champeme MH, Vidaud D, Lidereau R, Vidaud M. Novel approach to quantitative polymerase chain reaction using real-time detection: application to the detection of gene amplification in breast cancer. Int J Cancer. 1998 Nov 23;78(5):661-6. doi: 10.1002/(sici)1097-0215(19981123)78:53.0.co;2-i.
Reference Type
BACKGROUND
Hardingham JE, Kotasek D, Farmer B, Butler RN, Mi JX, Sage RE, Dobrovic A. Immunobead-PCR: a technique for the detection of circulating tumor cells using immunomagnetic beads and the polymerase chain reaction. Cancer Res. 1993 Aug 1;53(15):3455-8.
Reference Type
BACKGROUND
Denis MG, Lipart C, Leborgne J, LeHur PA, Galmiche JP, Denis M, Ruud E, Truchaud A, Lustenberger P. Detection of disseminated tumor cells in peripheral blood of colorectal cancer patients. Int J Cancer. 1997 Oct 21;74(5):540-4. doi: 10.1002/(sici)1097-0215(19971021)74:53.0.co;2-a.
Reference Type
BACKGROUND
Naume B, Borgen E, Beiske K, Herstad TK, Ravnas G, Renolen A, Trachsel S, Thrane-Steen K, Funderud S, Kvalheim G. Immunomagnetic techniques for the enrichment and detection of isolated breast carcinoma cells in bone marrow and peripheral blood. J Hematother. 1997 Apr;6(2):103-14. doi: 10.1089/scd.1.1997.6.103.
Reference Type
BACKGROUND
Eaton MC, Hardingham JE, Kotasek D, Dobrovic A. Immunobead RT-PCR: a sensitive method for detection of circulating tumor cells. Biotechniques. 1997 Jan;22(1):100-5. doi: 10.2144/97221st01.
Reference Type
BACKGROUND
Soria JC, Gauthier LR, Raymond E, Granotier C, Morat L, Armand JP, Boussin FD, Sabatier L. Molecular detection of telomerase-positive circulating epithelial cells in metastatic breast cancer patients. Clin Cancer Res. 1999 May;5(5):971-5.
Reference Type
BACKGROUND
Zhong XY, Kaul S, Lin YS, Eichler A, Bastert G. Sensitive detection of micrometastases in bone marrow from patients with breast cancer using immunomagnetic isolation of tumor cells in combination with reverse transcriptase/polymerase chain reaction for cytokeratin-19. J Cancer Res Clin Oncol. 2000 Apr;126(4):212-8. doi: 10.1007/s004320050035.
Reference Type
BACKGROUND
Rosenberg R, Gertler R, Friederichs J, Fuehrer K, Dahm M, Phelps R, Thorban S, Nekarda H, Siewert JR. Comparison of two density gradient centrifugation systems for the enrichment of disseminated tumor cells in blood. Cytometry. 2002 Dec 1;49(4):150-8. doi: 10.1002/cyto.10161.
Reference Type
BACKGROUND
Mitas M, Cole DJ, Hoover L, Fraig MM, Mikhitarian K, Block MI, Hoffman BJ, Hawes RH, Gillanders WE, Wallace MB. Real-time reverse transcription-PCR detects KS1/4 mRNA in mediastinal lymph nodes from patients with non-small cell lung cancer. Clin Chem. 2003 Feb;49(2):312-5. doi: 10.1373/49.2.312. No abstract available.
Reference Type
BACKGROUND
Bonner RF, Emmert-Buck M, Cole K, Pohida T, Chuaqui R, Goldstein S, Liotta LA. Laser capture microdissection: molecular analysis of tissue. Science. 1997 Nov 21;278(5342):1481,1483. doi: 10.1126/science.278.5342.1481. No abstract available.
Reference Type
BACKGROUND
Emmert-Buck MR, Bonner RF, Smith PD, Chuaqui RF, Zhuang Z, Goldstein SR, Weiss RA, Liotta LA. Laser capture microdissection. Science. 1996 Nov 8;274(5289):998-1001. doi: 10.1126/science.274.5289.998.
Reference Type
BACKGROUND
Pease AC, Solas D, Sullivan EJ, Cronin MT, Holmes CP, Fodor SP. Light-generated oligonucleotide arrays for rapid DNA sequence analysis. Proc Natl Acad Sci U S A. 1994 May 24;91(11):5022-6. doi: 10.1073/pnas.91.11.5022.
Reference Type
BACKGROUND
Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science. 1995 Oct 20;270(5235):467-70. doi: 10.1126/science.270.5235.467.
Reference Type
BACKGROUND
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74. doi: 10.1073/pnas.191367098.
Reference Type
BACKGROUND
Sgroi DC, Teng S, Robinson G, LeVangie R, Hudson JR Jr, Elkahloun AG. In vivo gene expression profile analysis of human breast cancer progression. Cancer Res. 1999 Nov 15;59(22):5656-61.
Reference Type
BACKGROUND
Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature. 2000 Aug 17;406(6797):747-52. doi: 10.1038/35021093.
Reference Type
BACKGROUND
Ahr A, Holtrich U, Solbach C, Scharl A, Strebhardt K, Karn T, Kaufmann M. Molecular classification of breast cancer patients by gene expression profiling. J Pathol. 2001 Oct;195(3):312-20. doi: 10.1002/path.955.
Reference Type
BACKGROUND
Ahr A, Karn T, Solbach C, Seiter T, Strebhardt K, Holtrich U, Kaufmann M. Identification of high risk breast-cancer patients by gene expression profiling. Lancet. 2002 Jan 12;359(9301):131-2. doi: 10.1016/S0140-6736(02)07337-3.
Reference Type
BACKGROUND
West M, Blanchette C, Dressman H, Huang E, Ishida S, Spang R, Zuzan H, Olson JA Jr, Marks JR, Nevins JR. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11462-7. doi: 10.1073/pnas.201162998. Epub 2001 Sep 18.
Reference Type
BACKGROUND
Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R, Meltzer P, Gusterson B, Esteller M, Kallioniemi OP, Wilfond B, Borg A, Trent J, Raffeld M, Yakhini Z, Ben-Dor A, Dougherty E, Kononen J, Bubendorf L, Fehrle W, Pittaluga S, Gruvberger S, Loman N, Johannsson O, Olsson H, Sauter G. Gene-expression profiles in hereditary breast cancer. N Engl J Med. 2001 Feb 22;344(8):539-48. doi: 10.1056/NEJM200102223440801.
Reference Type
BACKGROUND
Chicurel M. Faster, better, cheaper genotyping. Nature. 2001 Aug 9;412(6847):580-2. doi: 10.1038/35088146. No abstract available.
Reference Type
BACKGROUND
Hacia JG, Brody LC, Chee MS, Fodor SP, Collins FS. Detection of heterozygous mutations in BRCA1 using high density oligonucleotide arrays and two-colour fluorescence analysis. Nat Genet. 1996 Dec;14(4):441-7. doi: 10.1038/ng1296-441.
Reference Type
BACKGROUND
Hacia JG, Sun B, Hunt N, Edgemon K, Mosbrook D, Robbins C, Fodor SP, Tagle DA, Collins FS. Strategies for mutational analysis of the large multiexon ATM gene using high-density oligonucleotide arrays. Genome Res. 1998 Dec;8(12):1245-58. doi: 10.1101/gr.8.12.1245.
Reference Type
BACKGROUND
Staunton JE, Slonim DK, Coller HA, Tamayo P, Angelo MJ, Park J, Scherf U, Lee JK, Reinhold WO, Weinstein JN, Mesirov JP, Lander ES, Golub TR. Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10787-92. doi: 10.1073/pnas.191368598.
Reference Type
BACKGROUND
Alban A, David SO, Bjorkesten L, Andersson C, Sloge E, Lewis S, Currie I. A novel experimental design for comparative two-dimensional gel analysis: two-dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomics. 2003 Jan;3(1):36-44. doi: 10.1002/pmic.200390006.
Reference Type
BACKGROUND
Banks RE, Dunn MJ, Hochstrasser DF, Sanchez JC, Blackstock W, Pappin DJ, Selby PJ. Proteomics: new perspectives, new biomedical opportunities. Lancet. 2000 Nov 18;356(9243):1749-56. doi: 10.1016/S0140-6736(00)03214-1.
Reference Type
BACKGROUND
Adam PJ, Boyd R, Tyson KL, Fletcher GC, Stamps A, Hudson L, Poyser HR, Redpath N, Griffiths M, Steers G, Harris AL, Patel S, Berry J, Loader JA, Townsend RR, Daviet L, Legrain P, Parekh R, Terrett JA. Comprehensive proteomic analysis of breast cancer cell membranes reveals unique proteins with potential roles in clinical cancer. J Biol Chem. 2003 Feb 21;278(8):6482-9. doi: 10.1074/jbc.M210184200. Epub 2002 Dec 10.
Reference Type
BACKGROUND
Mikhitarian K, Reott S, Hoover L, Allen A, Cole DJ, Gillanders WE, Mitas M. Enhanced detection of RNA from paraffin-embedded tissue using a panel of truncated gene-specific primers for reverse transcription. Biotechniques. 2004 Mar;36(3):474-8. doi: 10.2144/04363RN01. No abstract available.
Reference Type
BACKGROUND
Mitas M, Mikhitarian K, Hoover L, Lockett MA, Kelley L, Hill A, Gillanders WE, Cole DJ. Prostate-Specific Ets (PSE) factor: a novel marker for detection of metastatic breast cancer in axillary lymph nodes. Br J Cancer. 2002 Mar 18;86(6):899-904. doi: 10.1038/sj.bjc.6600190.
Reference Type
BACKGROUND
Wallace MB, Block MI, Gillanders W, Ravenel J, Hoffman BJ, Reed CE, Fraig M, Cole D, Mitas M. Accurate molecular detection of non-small cell lung cancer metastases in mediastinal lymph nodes sampled by endoscopic ultrasound-guided needle aspiration. Chest. 2005 Feb;127(2):430-7. doi: 10.1378/chest.127.2.430.
Reference Type
BACKGROUND
Muller PY, Janovjak H, Miserez AR, Dobbie Z. Processing of gene expression data generated by quantitative real-time RT-PCR. Biotechniques. 2002 Jun;32(6):1372-4, 1376, 1378-9.
Reference Type
BACKGROUND
Mikhitarian, K., W.E. Gillanders, J.S. Almeida, R.H. Martin, J.C. Varela, J.S. Metcalf, D.J. Cole, and M. Mitas. 2005. Relative levels of gene expression are correlated with the ability to detect micrometastatic breast cancer: statistical analysis of data from a multi-institutional prospective cohort study and development of an innovative microarray strategy. Clin Cancer Res In Press.
Reference Type
BACKGROUND
Mitas M, Almeida JS, Mikhitarian K, Gillanders WE, Lewin DN, Spyropoulos DD, Hoover L, Graham A, Glenn T, King P, Cole DJ, Hawes R, Reed CE, Hoffman BJ. Accurate discrimination of Barrett's esophagus and esophageal adenocarcinoma using a quantitative three-tiered algorithm and multimarker real-time reverse transcription-PCR. Clin Cancer Res. 2005 Mar 15;11(6):2205-14. doi: 10.1158/1078-0432.CCR-04-1091.
Reference Type
BACKGROUND
Mikhitarian K, Martin RH, Mitas M, Mauldin PD, Palesch Y, Metcalf JS, Cole DJ, Gillanders WE; Mims Study Group. Molecular analysis improves sensitivity of breast sentinel lymph node biopsy: results of a multi-institutional prospective cohort study. Surgery. 2005 Sep;138(3):474-81. doi: 10.1016/j.surg.2005.07.001.
Reference Type
BACKGROUND
Related Links
Access external resources that provide additional context or updates about the study.
http://www.siteman.wustl.edu
Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
05-0435 / 201109033
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood & Primary Tumor in ER+/HER2- MBC
NCT04480814
COMPLETED
Prospective Validation Trial of Circulating Tumor Cells (CTCs) in Women With Metastatic Breast Cancer
NCT00493350
COMPLETED
Study of Tumor and Blood Samples From Women With Breast Cancer
NCT00897728
UNKNOWN
Molecular Analysis of Breast Cancer
NCT00569049
COMPLETED
Molecular Profiling of Stage II and III Breast Cancer in Latin American Women Receiving Standard-of-Care Treatment
NCT02326857
COMPLETED
Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification
NCT01839045
UNKNOWN
Immunomonitoring of Breast Cancer Patients During Systemic Treatment
NCT04925856
RECRUITING
NA
A Prospective Longitudinal Breast Cancer Study
NCT02270931
COMPLETED
Blood Sample Collection and Health Information Collection From Patients With Invasive Breast Cancer and Their Brothers and Sisters
NCT00445562
UNKNOWN
Predictive Role of New Biomarkers for Hypersensitive Patients to Radiation in Breast Cancer (BIORISE)
NCT03252717
ACTIVE_NOT_RECRUITING
NA
PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer
NCT02732171
RECRUITING
NA
Evaluation of Prognostic Monitoring for Young Breast Cancer Patients
NCT04145986
UNKNOWN
Multiplex Testing for Breast Cancer Susceptibility: A Pilot Study of Subject Preferences for Information and Responses After Testing
NCT01992471
COMPLETED
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
NCT03723928
RECRUITING
NA
MRD in High-risk EBC
NCT06566729
ACTIVE_NOT_RECRUITING
Studying Urine and Blood Samples in Women With Newly Diagnosed Breast Cancer
NCT00766454
COMPLETED
Praegnant Breast Cancer: Early/Advanced/Metastatic
NCT02338167
RECRUITING
The Association Between Age-related Peripheral Blood Components and Treatment Efficacy in Breast Cancer
NCT06718010
RECRUITING
A Study to Identify Breast Cancer (IDBC)
NCT04495244
UNKNOWN
Using a Blood Test to Monitor Metastatic Breast Cancer Treatment
NCT05804578
RECRUITING
Studying Blood and Tumor Tissue Samples in Women With Invasive Breast Cancer, Ductal or Lobular Carcinoma in Situ, or Benign Breast Disease
NCT00898508
COMPLETED
Identification of Biomarkers in Women at High Risk or Average Risk of Breast Cancer
NCT00897416
COMPLETED
Breast Cancer Risk Assessment in Women Aged 40-49
NCT03180086
COMPLETED
NA
Identification of Novel Genetic Factors That Contribute to Risk for Breast Cancer
NCT00276120
COMPLETED